Laboratory Animal and Comparative Medicine ›› 2026, Vol. 46 ›› Issue (2): 306-310.DOI: 10.12300/j.issn.1674-5817.2026.004
• Expert Voices • Previous Articles
Received:2026-01-04
Revised:2026-03-26
Online:2026-04-25
Published:2026-04-18
CLC Number:
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.slarc.org.cn/dwyx/EN/10.12300/j.issn.1674-5817.2026.004
| [1] | 孙强. 无替代,何谈取消[J]. 实验动物与比较医学, 2025, 45(3): 376-378. DOI: 10.12300/j.issn.1674-5817.2025.064 . |
| [2] | 孙强. 非动物实验替代知多少[J]. 实验动物与比较医学, 2025, 45(4): 508-514. DOI: 10.12300/j.issn.1674-5817.2025.117 . |
| [3] | 孙强. 类器官不是器官[J]. 实验动物与比较医学, 2025, 45(5): 649-654. DOI: 10.12300/j.issn.1674-5817.2025.148 . |
| [4] | 孙强. TG 497视角下动物实验完全替代的突破与困境[J]. 实验动物与比较医学, 2025, 45(6): 810-812. DOI: 10.12300/j.issn.1674-5817.2025.133 . |
| [5] | 孙强. FDA新政下减少非人灵长类实验动物使用量的可行路径[J]. 实验动物与比较医学, 2026, 46(1): 149-152. DOI: 10.12300/j.issn.1674-5817.2025.213 . |
| [6] | U.S. Food and Drug Administration. Generic Drugs Undergo Rigorous FDA Review[EB/OL]. (2022-09-16)[2026-01-02]. https://www.fda.gov/consumers/consumer-updates/generic-drugs-undergo-rigorous-fda-review. |
| [7] | BLOSSOM D B, KALLEN A J, PATEL P R, et al. Outbreak of adverse reactions associated with contaminated heparin[J]. N Engl J Med, 2008, 359(25): 2674-2684. DOI: 10.1056/NEJMoa0806450 . |
| [8] | HUECKER M R, SMILEY A, SAADABADI A. Bupropion[M/OL]//StatPearls. Treasure Island (FL): StatPearls Publishing, 2024-09-02)[2026-01-02]. https://www.ncbi.nlm.nih.gov/books/NBK470212/. |
| [9] | U.S. Food and Drug Administration. Update: Bupropion Hydrochloride Extended-Release 300 mg Bioequivalence Studies[EB/OL]. (2014-10-02)[2026-01-02].https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/update-bupropion-hydrochloride-extended-release-300-mg-bioequivalence-studies. |
| [10] | SINCLAIR L. Generic bupropion product withdrawn from market[J]. Psychiatr News, 2012, 47(21): 4-17. DOI: 10.1176/pn.47.21.psychnews_47_21_4-a . |
| [11] | SEDLO I, KOLONIĆ T, TOMIĆ S. Presence of nitrosamine impurities in medicinal products[J]. Arh Hig Rada Toksikol, 2021, 72(1): 1-5. DOI: 10.2478/aiht-2021-72-3491 . |
| [12] | FARRUKH M J, TARIQ M H, MALIK O, et al. Valsartan recall: global regulatory overview and future challenges[J]. Ther Adv Drug Saf, 2019, 10: 2042098618823458. DOI: 10.1177/2042098 618823458 . |
| [13] | U.S. Food and Drug Administration. FDA updates and press announcements on angiotensin Ⅱ receptor blocker (ARB) recalls (valsartan, losartan, and irbesartan)[EB/OL]. (2019-11-13)[2026-01-02]. . |
| [14] | CENZIPER D, ROSE M. The FDA often doesn't test generic drugs for quality concerns, so ProPublica did[EB/OL]. (2025-12-22)[2026-01-02]. https://www.propublica.org/article/fda-generic-drug-testing. |
| [15] | Association for Accessible Medicines. 2025 U.S. generic & biosimilar medicines savings report[R/OL]. [2026-01-02]. https://accessiblemeds.org/resources/reports/2025-savings-report/. |
| [16] | Commission European. EudraLex Volume 4: EU guidelines for good manufacturing practice for medicinal products for human and veterinary use[EB/OL]. (2022-02-21)[2026-01-02]. https://health.ec.europa.eu/latest-updates/eudralex-volume-4-eu-guidelines-good-manufacturing-practice-medicinal-products-human-and-veterinary-2022-02-21_en. |
| [17] | U.S. Food and Drug Administration. Intas Pharmaceuticals Ltd. Intas Pharmaceuticals Limited[EB/OL]. (2023-08-01)[2026-01-02]. https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/intas-pharmaceuticals-limited-652067-07282023. |
| [18] | ADASHI E Y, O'MAHONY D P, COHEN I G. The FDA Modernization Act 2.0: drug testing in animals is rendered optional[J]. Am J Med, 2023, 136(9): 853-854. DOI: 10.1016/j.amjmed.2023.03.033 . |
| [19] | U.S. Food and Drug Administration. FDA Announces Plan to Phase out Animal Testing Requirement for Monoclonal Antibodies and Other Drugs[EB/OL]. (2025-04-10)[2026-01-02]. https://www.fda.gov/news-events/press-announcements/fda-announces-plan-phase-out-animal-testing-requirement-monoclonal-antibodies-and-other-drugs. |
| [20] | 孙强. 为什么要开展动物实验[J]. 实验动物与比较医学, 2024, 44(1): 121-126. DOI: 10.12300/j.issn.1674-5817.2023.177s . |
| [1] | ZHANG Jiaoling, LIN Aping, XU Shiying, PAN Dequan, CAI Yijun. Optimization and Application of Mouse Embryo Transfer Technology [J]. Laboratory Animal and Comparative Medicine, 2026, (): 1-9. |
| [2] | . [J]. Laboratory Animal and Comparative Medicine, 2026, 46(4): 611-613. |
| [3] | MA Wenjing, LIU Yanping, LI Yifan, GUO Huan, XIE Lihui, DU Longji, MA Jiali, WANG Hongping, LI Jiamin. Practice in Validity Period Management of Disinfectants, Feed, and Bedding in Laboratory Animal Facilities under Good Laboratory Practice Management System [J]. Laboratory Animal and Comparative Medicine, 2026, 46(4): 593-603. |
| [4] | WANG Lu, WANG Qingjie, YANG Chunhong, ZHANG Yijian. Application of New Approach Methodologies in Biomedical Field and Their Implementation of "3R" Principle [J]. Laboratory Animal and Comparative Medicine, 2026, 46(4): 573-582. |
| [5] | QIANG Sujing, LI Dongting, XU Jinhua, CAI Li, WEI Siyu, ZOU Jialei, DING Yuqiang. Identification and Analysis of the Klebsiella pneumoniae Species Complex in Laboratory Rats and Mice [J]. Laboratory Animal and Comparative Medicine, 2026, 46(4): 564-572. |
| [6] | LI Hongman, CHEN Yutong, SHI Yingpei, WANG Yijing, PAN Yan, XU Tong, ZHOU Yi, DENG Qiyue, LIU Xue. A New Perspective on Mental Health Assessment in Laboratory Animals: Stress Response Monitoring Based on Hair Characteristics [J]. Laboratory Animal and Comparative Medicine, 2026, 46(4): 553-563. |
| [7] | LEI Jianjun, SUO Chenhao, ZHANG He. Resveratrol Alleviates Blood‑Brain Barrier Damage in Cerebral Ischemia‑Reperfusion Rat Models through Modulation of the CCL3/CCR5 Signaling Pathway [J]. Laboratory Animal and Comparative Medicine, 2026, 46(4): 487-497. |
| [8] | LI Chunyang, LIU Xingchen, LI Yuzhuo, LU Yong, WANG Yan, GAO Changshan, NIE Yanhong, BIAN Xinyan, HU Chao, ZHU Jiaqiao, SUN Qiang. Generation of Cynomolgus and Rhesus Monkey Models Carrying the BMPR1BFecB Variant [J]. Laboratory Animal and Comparative Medicine, 2026, 46(4): 467-475. |
| [9] | LIU Liang, CHEN Bin, MEN Li, ZHANG Huan, LIU Jinzhou, LIU Keliang, LI Yangyou, DUAN Jiahui, YAN Jintai, YANG Guolin, JIN Bo. Serving National Strategies and the Chengdu-Chongqing Biomedical Industry: Innovative Layout and Practical Pathways of Undergraduate Education in Laboratory Animal Science [J]. Laboratory Animal and Comparative Medicine, 2026, (): 1-12. |
| [10] | YANG Ran, FENG Jiwei, MA Fei, ZHANG Yu, LIU Zhiwei, JIIN Lilun. Fraxetin Inhibits Ferroptosis and Alleviates Cartilage Damage in Osteoarthritis Rat Through Nrf2/HO-1 Signaling Pathway [J]. Laboratory Animal and Comparative Medicine, 2026, (): 1-12. |
| [11] | AI Xiufeng, ZHANG Lizong, FANG Mingsun, LÜ Dongying, CHEN Chu, CAI Zhaowei, WANG Dejun. Analysis of Differences in the Intestinal Flora of Rats and Mice after Drinking Chlorinated Water Based on 16S rRNA Sequencing [J]. Laboratory Animal and Comparative Medicine, 2026, 46(3): 437-445. |
| [12] | ZHOU Yimin, ZHANG Xinyu, YANG Jianuo, LIU Mengjia, SI Cancan, YE Hailü, SUN Wenchao, LAN Tian. Development of a Triplex TaqMan Quantitative PCR Method for Simultaneous Detection of MHV, MPV, and Reo-3 [J]. Laboratory Animal and Comparative Medicine, 2026, 46(3): 408-415. |
| [13] | . [J]. Laboratory Animal and Comparative Medicine, 2026, 46(3): 464-466. |
| [14] | CHEN Lin, ZHANG Housen, AI Man, QI Chongyang. Research on the High-Quality Development Path of Laboratory Animal Management in Jiangsu Province Empowered by Digital Transformation [J]. Laboratory Animal and Comparative Medicine, 2026, 46(3): 426-436. |
| [15] | LI Longxue, WAN Chongfan, ZHANG Qi, LEI Ruting, WANG Xiaoyue, CHENG Leyan, LAI Qi, LIU Ronghua, LIU Xuan, XU Tielong. Molecular Mechanisms of Qingfei Paidu Decoction in the Prevention and Treatment of Acute Lung Injury in Mice Based on miRNA Sequencing [J]. Laboratory Animal and Comparative Medicine, 2026, 46(3): 311-320. |
| Viewed | ||||||
|
Full text |
|
|||||
|
Abstract |
|
|||||
